Results 31 to 40 of about 3,654 (190)

Sofosbuvir-Based Therapies Achieved Satisfactory Virological Response in Chinese Individuals with Genotypes 3 and 6 Infections: A Real-World Experience

Infection and Drug Resistance, 2021
Qiao Tang, Li Wei, Xiaoqing Liu, Peng Hu Department of Infectious Diseases, Institute for Viral Hepatitis, The Key Laboratory of Molecular Biology for Infectious Diseases, Chinese Ministry of Education, The Second Affiliated Hospital of Chongqing Medical
Tang Q, Wei L, Liu X, Hu P
doaj  

Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries

Journal of Virus Eradication, 2020
Objectives: Seven years after the introduction of direct-acting antivirals (DAAs) for the treatment of hepatitis C, high prices remain a barrier for treatment programs worldwide.
Melissa J. Barber, Dzintars Gotham, Giten Khwairakpam, Andrew Hill   +3 more
doaj   +1 more source

Safety and efficacy of sofosbuvir plus velpatasvir with or without ribavirin for chronic hepatitis C virus infection: A systematic review and meta-analysis

Journal of Infection and Public Health, 2018
Velpatasvir is a newly FDA-approved inhibitor of hepatitis C virus (HCV) NS5A protein. We performed this systematic review and meta-analysis to investigate the safety and efficacy of velpatasvir plus sofosbuvir in the treatment of chronic HCV infection ...
Hussien Ahmed, Abdelrahman I. Abushouk, Attia Attia, Mohamed Gadelkarim, Mohamed Gabr, Ahmed Negida, Mohamed M. Abdel-Daim   +6 more
doaj   +1 more source

Efectividad del tratamiento de la hepatitis C en pacientes atendidos en la consulta de atención farmacéutica

Ars Pharmaceutica, 2020
RESUMEN Objetivos: Determinar la efectividad del tratamiento de la hepatitis C crónica definida como la respuesta viral sostenida a las 12 semanas (RVS12) tras la finalización del tratamiento con fármacos antivirales de acción directa (AAD ...
José Miguel Sotoca-Momblona, Montserrat Rodriguez-Reyes, Neus Pagès-Puigdemont, Concepció Bartres-Viñas, Sergio Rodriguez-Tajes, Sabela Lens-García, Zoe Mariño-Mendez   +6 more
doaj   +1 more source

Use of glecaprevir and pibrentasvir as rescue therapy in patients with resistance to direct-acting antiviral agents

Annals of Hepatology, 2022
Introduction and Objective: Hepatitis C virus infection is one of the main causes of chronic liver disease. Treatment with direct-acting antivirals (DAAs) has shown high efficacy in achieving sustained viral response with a low risk of relapse. There are
LS Juarez Chavez, JS Sandoval Mendoza
doaj   +1 more source

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

, 2017
BACKGROUND: Patients who are chronically infected with hepatitis C virus (HCV) and who do not have a sustained virologic response after treatment with regimens containing direct-acting antiviral agents (DAAs) have limited retreatment options. METHODS: We
Bansal, Meena B, Michael P. Manns, Stephen Pianko, Younes, Ziad, Mchutchison, John, G., Landis, Charles, S, Natarajan Ravendhran, Robert H. Hyland, Flamm, Steven L, Cooper, Curtis, Younes, Ziad H, Tran, Tram, Curry, Michael, Tran, Tram T, Manns, Michael, Huang, K.C., Huang, K C, Reddy, K R, Schiff, Eugene, Curtis L. Cooper, Jie Zhang, Brainard, Diana M, Simone I. Strasser, Michael P. Curry, Steven L. Flamm, Pianko, Stephen, Svarovskaia, Evguenia, Charles S. Landis, Peter Buggisch, Buggisch, Peter, Diana M. Brainard, G. Mani Subramanian, Stamm, Luisa, Stuart C. Gordon, Marc Bourlière, Zhang, Jie, Flamm, Steven, L., Kowdley, Kris, V., John G. McHutchison, Bourlière, Marc, Ravendhran, Natarajan, Hadas Dvory-Sobol, Curry, Michael P, Stefan Zeuzem, Luisa M. Stamm, Brainard, Diana, K. Rajender Reddy, Tram T. Tran, Eugene R. Schiff, Alnoor Ramji, Evguenia Svarovskaia, McHutchison, John G, Vierling, John, Ramji, Alnoor, Reddy, K. Rajender, Subramanian, G. Mani, Kris V. Kowdley, Subramanian, G M, Cooper, Curtis L, Dvory-Sobol, Hadas, Hyland, Robert, John M. Vierling, Huang, K.C, Verna, Elizabeth C, Strasser, Simone I, Bansal, Meena, Victor de Lédinghen, K.C. Huang, de Lédinghen, Victor, Landis, Charles S, Elizabeth C. Verna, Subramanian, G Mani, Hyland, Robert H, Stamm, Luisa M, Gordon, Stuart, Myron Tong, Meena B. Bansal, Ziad H. Younes, Kowdley, Kris V, Reddy, K Rajender, Gordon, Stuart C, Strasser, Simone, Verna, Elizabeth, Manns, Michael P, Tong, Myron, Schiff, Eugene R, Vierling, John M, Zeuzem, Stefan   +87 more
core   +1 more source

Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis

, 2015
As the population that is infected with the hepatitis C virus (HCV) ages, the number of patients with decompensated cirrhosis is expected to increase.
Doehle, Brian, Schiff, Eugene, Fried, Michael, Bzowej, Natalie, An, Di, Curry, Michael P, Teperman, Lewis, Flamm, Steven L, McHutchison, John G, O'Leary, Jacqueline G, Fontana, Robert, Brown, Jr, Robert S, Fenkel, Jonathan M, Schiano, Thomas, Brainard, Diana M, Lawitz, Eric, ASTRAL-4 Investigators, Muir, Andrew J, Korenblat, Kevin M, McNally, John, Reddy, K Rajender, Osinusi, Anu, Charlton, Michael   +22 more
core   +1 more source

Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C

, 2018
Compliance with Ethical StandardsFunding: The preparation of this review was not supported by any external funding.Conflicts of interest: Young-A Heo and Emma Deeks are salaried employees of Adis/Springer, are responsible for the article content and ...
Young-A Heo (4077493), Emma D. Deeks (4985339)   +1 more
core   +1 more source

Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis [PDF]

, 2019
[Background & Aims] Although off-label use of sofosbuvir-containing regimens occurs regularly in patients with hepatitis C virus (HCV) infection undergoing dialysis for severe renal impairment or end-stage renal disease (ESRD), these regimens are not ...
Agarwal, Kosh, Ben-Ari, Ziv, Lurie, Yoav, Cramp, Matthew E., Markova, Svetlana, Bruck, Rafael, Osinusi, Anu O, Calleja, José Luis, Fernández-Rodríguez, Conrado M., Ampuero, Javier, Gane, Edward J., Borgia, Sergio M, Rodriguez, Conrado Fernandez, Haider, Shariq, Willems, Bernard, Cooper, Curtis, Yoshida, Eric M, Borgia, Sergio M., Dvory-Sobol, Hadas, Brown, Ashley, Hyland, Robert, Shafran, Stephen D, Cramp, Matthew E, Esteban, Rafael, Osinusi, Anu O., Ryder, Stephen D., Gane, Edward J, Kirby, Brian J, Lu, Sophia, Fox, Raymond, Meng, Amy, Dearden, Janet, Kirby, Brian J., Shaw, David, Yoshida, Eric M., Ryder, Stephen D, Shafran, Stephen D., Foxton, Matthew   +37 more
core   +1 more source

Curing of chronic hepatitis C combined with coronavirus disease 2019 in a couple over 85 years old: a case series study

Frontiers in Microbiology
IntroductionData on the management of patients aged more than 85 years with chronic hepatitis C virus (HCV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequential infections are lacking.MethodsThe current study described the ...
Qing-Lei Zeng, Xue-Yan Lv, Ru-Yue Chen, Ya-Jie Pan   +3 more
doaj   +1 more source